Abstract 4274
Background
Cediranib and olaparib have shown efficacy in ovarian cancer (OC) throughout several clinical settings. A phase II study demonstrated that the combination of the two drugs increased progression free survival (PFS) in women with recurrent platinum sensitive OC with respect to olaparib (Liu et al, 2014). The greatest benefit from the combination was observed in wild-type/unknown BRCA patients, therefore suggesting a possible effect of the combination in platinum resistant OC which are mainly BRCA proficient tumors. The most frequent grade ≥ 3 AEs with the combination were hypertension, diarrhea and fatigue, suggesting an amplificatory effect caused by cediranib. The purpose of this study is to test the efficacy of olaparib/cediranib combination in platinum resistant disease, comparing this regimen with weekly paclitaxel, and to identify a more tolerable schedule for this combination treatment.
Trial design
This is a randomized multicenter phase II open label study. Patients with platinum resistant OC will be randomized in a 1:1:1 ratio in a control and two experimental arms. Control treatment consists of administration of 80 mg/m2 weekly paclitaxel, up to a maximum of 24 weeks or to progression. Combination therapy is administered up to progression with two different schedules: i. Continuous with 600 mg olaparib (tablets) and 20 mg cediranib given every day; ii. Intermittent with 600 mg olaparib (tablets) given every day and 20 mg cediranib given 5 days/week. The study has two primary endpoints: 1) PFS, to compare the efficacy between control and experimental arms with a 80% power to detect a benefit ≥ 3.3 months and, 2) the number of evacuations/day in the first 28 days of the combination therapy as tolerability indicator. If both experimental arms show superiority - in terms of PFS - to control treatment, these will be compared for tolerability. The study is registered at clinicaltrials.gov (NCT03314740) and is currently recruiting. Eighty-seven patients out of 100 planned have already been enrolled from 6 experimental sites in Italy in 11 months.
Clinical trial identification
EudraCT: 2016-003964-38; NCT03314740.
Legal entity responsible for the study
IRCCS Istituto di Ricerche Farmacologiche Mario Negri di Milano.
Funding
AstraZeneca.
Editorial Acknowledgement
Disclosure
N. Colombo: Immediate family member has been employed by Ignyta during the past 2 years; Honoraria: F. Hoffmann-La Roche Ltd, AstraZeneca, PharmaMar, Clovis, Tesaro, Pfizer during the past 2 years; Consulting or advisory role: F. Hoffmann-La Roche Ltd, AstraZeneca, PharmaMar, Clovis, Tesaro, Pfizer during the past 2 years; Travel, accommodations and other expenses: F. Hoffmann-La Roche Ltd, PharmaMar, AstraZeneca, Tesaro during the past 2 years. A.A. Lissoni: Travel, accommodations and other expenses: F. Hoffmann-La Roche Ltd during the past 2 years. R. Fossati: Travel, accommodations and other expenses: PharmaMar during the past 2 years. All other authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract